83 related articles for article (PubMed ID: 21533450)
1. Effect of specific activity on organ uptake of iodine-123-meta-iodobenzylguanidine in humans.
Farahati J; Lassmann M; Scheubeck M; Bier D; Hanscheid H; Schelper L; Grelle I; Biko J; Werner E; Graefe K; Reiners C
Int J Oncol; 1997 Apr; 10(4):815-9. PubMed ID: 21533450
[TBL] [Abstract][Full Text] [Related]
2. Effect of specific activity on cardiac uptake of iodine-123-MIBG.
Farahati J; Bier D; Scheubeck M; Lassmann M; Schelper LF; Grelle I; Hanscheid H; Biko J; Graefe KH; Reiners C
J Nucl Med; 1997 Mar; 38(3):447-51. PubMed ID: 9074536
[TBL] [Abstract][Full Text] [Related]
3. Effect of specific activity on neuroblastoma uptake of I-123-meta-iodobenzylguanidine in nude mice xenografted with SK-N-SH cells.
Farahati J; Coenen H; Dutschka K; Stuben G; Knuhmann K; Budach W; Kremens B; Reiners C
Oncol Rep; 1997; 4(2):363-6. PubMed ID: 21590060
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
6. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
7. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylpropylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats.
Samnick S; Scheuer C; Münks S; El-Gibaly AM; Menger MD; Kirsch CM
Nucl Med Biol; 2004 May; 31(4):511-22. PubMed ID: 15093822
[TBL] [Abstract][Full Text] [Related]
9. [A simple and rapid routine preparation of no-carrier added meta-I-123- and I-131-iodobenzylguanidine (I-123-MIBG and I-131-MIBG) for clinical nuclear medicine applications].
Samnick S; Kirsch CM
Nuklearmedizin; 1999; 38(7):292-6. PubMed ID: 10599069
[TBL] [Abstract][Full Text] [Related]
10. A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells.
Vaidyanathan G; Affleck DJ; Norman J; O'Dorisio S; Zalutsky MR
Bioconjug Chem; 2007; 18(6):2122-30. PubMed ID: 17979223
[TBL] [Abstract][Full Text] [Related]
11. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
12. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Appl Radiat Isot; 2005 Mar; 62(3):435-40. PubMed ID: 15607920
[TBL] [Abstract][Full Text] [Related]
13. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
14. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Nucl Med; 1995 Apr; 36(4):644-50. PubMed ID: 7699460
[TBL] [Abstract][Full Text] [Related]
15. Radiosynthesis of no-carrier-added
Green M; Lowe J; Kadirvel M; McMahon A; Westwood N; Chua S; Brown G
J Radioanal Nucl Chem; 2017; 311(1):727-732. PubMed ID: 28111488
[No Abstract] [Full Text] [Related]
16. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
17. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
18. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology.
Vallabhajosula S; Nikolopoulou A
Semin Nucl Med; 2011 Sep; 41(5):324-33. PubMed ID: 21803182
[TBL] [Abstract][Full Text] [Related]
19. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
20. Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.
Armour A; Mairs RJ; Gaze MN; Wheldon TE
Br J Cancer; 1994 Sep; 70(3):445-8. PubMed ID: 8080728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
